Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07142304

The Lilac Device Trial

Led by Luminate Medical, Inc. · Updated on 2026-04-02

142

Participants Needed

15

Research Sites

51 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Chemotherapy drugs, used in the treatment of cancer, have the potential of inducing peripheral neuropathy (PN) as a side effect. This side effect is commonly referred to as CIPN, or chemotherapy-induced peripheral neuropathy. The Lilac Glove and Boot devices apply a low pressure across the surface of the hands and feet, respectively, to reduce access of chemotherapy to the peripheral nerves on the hands and feet. The small amount of pressure reduces the level of chemotherapy reaching the peripheral nerves, hence increasing the likelihood of nerve preservation during treatment and thus may potentially temporarily prevent the onset of moderate to severe PN symptoms induced by chemotherapy in the hands and feet while receiving treatment

CONDITIONS

Official Title

The Lilac Device Trial

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 or older diagnosed with solid tumor cancer and planned for neo-adjuvant or adjuvant chemotherapy
  • Planned intravenous chemotherapy with at least 4 cycles without planned surgery pause
  • Chemotherapy regimens based on Oxaliplatin (FOLFOX or FOLFIRINOX), single-agent Paclitaxel, or Paclitaxel with Carboplatin
  • Concurrent use of targeted agents or immunotherapy at standard doses allowed
  • Hands and feet size within specified study sizing range
  • Plan to complete taxane- or platinum-based chemotherapy within 12 months
  • ECOG performance status between 0 and 2
  • Willing and able to sign informed consent
  • Willing to wear the Lilac devices as prescribed and complete all study questionnaires
  • Able to complete questionnaires in the languages available to the study
Not Eligible

You will not qualify if you...

  • Existing peripheral neuropathy of any kind at baseline (NCI CTCAE v5.0 grade > 0)
  • Prior neurotoxic chemotherapy in the previous 1 year
  • Positive pregnancy test for participants with childbearing potential
  • Known or suspected allergy to components of the Lilac devices including natural rubber latex
  • Open wounds, sores, cysts, or injuries on hands, feet, or areas where devices will be applied
  • Clinically significant peripheral arterial ischemia
  • Untreated or uncontrolled hypertension
  • Poorly controlled diabetes
  • Weight over 140 kg at enrollment
  • History or suspicion of hand or foot metastasis
  • Use of other investigational devices or active compression/cryotherapy for CIPN during the study
  • Receiving neuropathy-directed systemic therapies at enrollment (e.g., Pregabalin, Gabapentin, Amitriptyline, Nortriptyline, Venlafaxine, Duloxetine)
  • Cognitive impairment, psychiatric conditions, or mobility limitations preventing study compliance
  • Current or recent participation in a clinical study affecting peripheral neuropathy
  • Prior participation in this study at an earlier stage

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 15 locations

1

Palomar Health (Topography)

Poway, California, United States, 92064

Withdrawn

2

Eastern Connecticut Hematology Oncology

Norwich, Connecticut, United States, 06360

Actively Recruiting

3

Hialeah Hospital

Hialeah, Florida, United States, 33013

Actively Recruiting

4

Hawaii Cancer Care

Honolulu, Hawaii, United States, 96813

Actively Recruiting

5

Hope and Healing Cancer Services

Hinsdale, Illinois, United States, 60521

Actively Recruiting

6

Parkview Cancer Institute

Fort Wayne, Indiana, United States, 46845

Actively Recruiting

7

Health Partners Frauenshuh Cancer Center

Minneapolis, Minnesota, United States, 55426

Actively Recruiting

8

Fairview Masonic Cancer Clinic, University of Minnesota

Minneapolis, Minnesota, United States, 55455

Actively Recruiting

9

Astera Cancer Care

East Brunswick, New Jersey, United States, 08816

Actively Recruiting

10

New York Cancer and Blood Specialists

New York, New York, United States, 11967

Actively Recruiting

11

Springfield Regional Cancer Center

Springfield, Ohio, United States, 45502

Actively Recruiting

12

Mercy Health St. Elizabeth Hospital

Youngstown, Ohio, United States, 44512

Actively Recruiting

13

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, United States, 37232

Actively Recruiting

14

Hospital Sisters Health System - St.Vincent & St.Mary's

Green Bay, Wisconsin, United States, 54301

Actively Recruiting

15

St. James Hospital

Dublin, Dublin, Ireland

Actively Recruiting

Loading map...

Research Team

L

Lalita K Kota, M.S.

CONTACT

B

Barbara Oliveira, Ph.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here